

# Experimental And Applied Immunotherapy

[DOWNLOAD HERE](#)

1;Experimental and Applied Immunotherapy;3 1.1;Copyright;4 1.2;Foreword (Prcis);5 1.3;Contents;9  
1.4;Contributors;13 1.5;Part I T Cell Therapy: State-of-the-Art;19 1.5.1;Chapter 1: Extending the Use of  
Adoptive T Cell Immunotherapy for Infections and Cancer;20 1.5.1.1;Current State of Translational T Cell  
Therapy;21 1.5.1.1.1;Immunotherapy for Viral Infections Post-HSCT;21 1.5.1.1.1.1;Cytomegalovirus  
(CMV);21 1.5.1.1.1.2;Epstein-Barr Virus (EBV);21 1.5.1.1.1.3;Other Viruses;22 1.5.1.1.2;Immunotherapy  
for Virus-Associated Malignancies;22 1.5.1.1.2.1;EBV Lymphoma;22 1.5.1.1.3;Immunotherapy for  
Melanoma;25 1.5.1.1.3.1;T Cells Directed Against Nonviral Antigens;27 1.5.1.2;Classification of Tumor  
Antigens;28 1.5.1.2.1;Tumor Antigens and T-Cell Immunogenicity;28 1.5.1.2.2;Identification of Novel  
Tumor Antigens;28 1.5.1.2.3;Optimizing Cell Culture Protocols for Tumor-Specific CTL Generation;29  
1.5.1.2.4;Antigen-Presenting Cells (APCs);29 1.5.1.2.5;Cytokines;30 1.5.1.3;Genetic Modification of T  
Cells;31 1.5.1.3.1;Redirecting T-cell Specificity (Genetic Modification);31 1.5.1.3.2;TCR Gene Transfer;31  
1.5.1.3.3;Genetic Modification with Chimeric Antigen Receptors;34 1.5.1.3.3.1;Clinical Studies;34  
1.5.1.4;Genetic Modification of T Cells to Improve in vivo Proliferation and Survival;35 1.5.1.4.1;T-cell  
Persistence and Survival in vivo;35 1.5.1.4.2;T-cell Sources for Genetic Modification;36 1.5.1.4.3;Gene  
Modification to Enhance T-Cell Proliferation;36 1.5.1.4.4;Manipulating the Infused T Cells to Counteract  
Tumor Evasion Strategies;37 1.5.1.4.5;Genetic Modification of T Cells to Improve Safety;38  
1.5.1.4.5.1;Suicide Genes;38 1.5.1.4.5.2;Targeted Integration;39 1.5.1.4.6;Counteracting the Tumor  
Microenvironment;40 1.5.1.4.6.1;Nonspecific Lymphodepletion;40 1.5.1.4.6.2;Specific Treg Depletion;40  
1.5.1.4.7;Scale-Up of Tumor CTL Therapy;41 1.5.1.4.8;Simplify Large-Scale CTL Production;41 1.5.1.4.9;  
Off the Shelf. CTLs Cells;42 1.5.1.4.10;Cost Effectiveness of Adoptive T-Cell Therapy versus  
Conventional Therapies;43 1.5.1.5;References;44 1.6;Part II Non-T Cell Therapeutic Approaches;51  
1.6.1;Chapter 2: B Lymphocytes in Cancer Immunology;52 1.6.1.1;Introduction;53 1.6.1.1.1;Peripheral  
Human B-cell Development;53 1.6.1.1.2;B-Cell Effector States;55 1.6.1.1.3;B Cells and Cancer;57  
1.6.1.1.3.1;Serology;57 1.6.1.1.3.2;Tumor-Infiltrating B Cells;58 1.6.1.1.4;B Cells and Cancer: Friends or  
Foes?;58 1.6.1.1.5;Evidence for a Protective Effect of B Cells in Antitumor Responses;59

1.6.1.1.6;Evidence for a Negative Effect of B Cells on Antitumor Responses;60 1.6.1.1.7;Chronic Lymphocytic Leukemia as a Paradigm for Tumor Promotion by B Cells;62 1.6.1.2;B-Cell-Directed Cancer Immunotherapy;64 1.6.1.2.1;Eliminating Negative B-Cell Effects;64 1.6.1.3;Promoting Positive B-Cell Effects;65 1.6.1.3.1;Vaccines and Recombinant Antibodies;65 1.6.1.3.2;Enhancing B-cell Activity In situ;66 1.6.1.3.3;Adoptive B-Cell Transfer;66 1.6.1.4;References;67 1.6.2;Chapter 3: Monoclonal Antibody Therapy for Cancer;73 1.6.2.1;General Considerations;73 1.6.2.1.1;Introduction;73 1.6.2.1.2;Precision and Predictability;75 1.6.2.1.3;From Hematologic to Solid Malignancies;76 1.6.2.1.4;Direct and Indirect Mechanisms of Activity;80 1.6.2.1.5;Antigen;81 1.6.2.2;Antibody Engineering;82 1.6.2.2.1;Structural Features;82 1.6.2.2.2;Chimeric, Humanized, and Fully Human mAbs;83 1.6.2.2.3;Fc Engineering;85 1.6.2.2.4;Beyond IgG;85 1.6.2.3;Clinical Performance;86 1.6.2.3.1;Overview;86 1.6.2.3.2;CD20 Targeting;87 1.6.2.3.2.1;ERBB Receptor Family Targeting;88 1.6.2.3.2.2;VEGFA Targeting;90 1.6.2.4;Outlook;91 1.6.2.5;References;92 1.6.3;Chapter 4: Natural Killer Cells for Cancer Immunotherapy;98 1.6.3.1;NK Cell Development and Identification;98 1.6.3.2;Effector Functions of NK Cells;100 1.6.3.3;NK-Target Cell Recognition and Regulation by Cell Surface Receptors;101 1.6.3.4;Inhibitory Receptors;103 1.6.3.4.1;KIRs;10 EAN/ISBN : 9781607619802  
Publisher(s): Springer, Berlin, Springer Science & Business Media Discussed keywords: Immuntherapie, Krebs (Krankheit) Format: ePub/PDF Author(s): Medin, Jeffrey - Fowler, Daniel

[DOWNLOAD HERE](#)

Similar manuals: